Facebook
Twitter
LinkedIn
WhatsApp

Articles

Faslodex + Capivasertib vs Placebo in Metastatic, ER positive Breast Cancer

Published February 5, 2020 Background Capivasertib (AZD5363) is an oral inhibitor of AKT and by that it influences cell division, apoptosis and cell metabolism. The

Read More »

Triple Negative Breast Cancer patients – Capivasertib helps you survive

PURPOSE OF THE STUDY The trial was designed to evaluate the safety and efficacy of adding Capivasertib to Taxol as first-line therapy for metastatic TNBC

Read More »

HER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201

When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium,

Read More »

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, are our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics